Coartem

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2001-2017
051020012017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
OBJECTIVE To compare, in a phase IV trial, the efficacy and tolerability of artesunate-amodiaquine (Camoquin plus) dosed at 300… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Background. Artemisinin-based combination therapy (ACT) reduces microscopically confirmed gametocytemia and mosquito infection… (More)
Is this relevant?
2006
2006
In April 2004, 137 children 6-59 months of age with uncomplicated Plasmodium falciparum (Pf) malaria (Caala, Central Angola) were… (More)
  • figure 1
  • table 1
Is this relevant?
2006
2006
From 2001 to 2003, anti-malarial combination coartem and fansimef, recommended by WHO, were used to treat falciparum malaria in… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Artemisinin derivative-based combination therapy is expected to suppress the development of Plasmodium falciparum drug resistance… (More)
  • table 1
  • table 2
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Approximately one million children die from malaria each year. A recently approved artemisinin-based tablet, Coartem (co… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2005
Highly Cited
2005
BACKGROUND Resistance of malaria parasites to chloroquine (CQ) and sulphadoxine-pyrimethamine (SP) is increasing in prevalence in… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Measuring baseline levels of adherence and identifying risk factors for non-adherence are important steps before the introduction… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
Is this relevant?
2003
2003
An open randomized comparison of two-fixed dose artemisinin derivative-containing combination regimens was conducted in adults… (More)
Is this relevant?
Highly Cited
2001
Highly Cited
2001
The efficacy-safety and pharmacokinetics of the six-dose regimen of artemether-lumefantrine (Coartem/Riamet; Novartis Pharma AG… (More)
Is this relevant?